Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11β-hydroxysteroid dehydrogenase type 1
- 1 February 2003
- journal article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 143-144, 459-468
- https://doi.org/10.1016/s0009-2797(02)00221-1
Abstract
No abstract availableKeywords
Funding Information
- Ministerstvo Školství, Mládeže a Tělovýchovy (LN00B125)
- Deutsche Forschungsgemeinschaft (MA 1704/3-2)
This publication has 20 references indexed in Scilit:
- Minireview: 11β-Hydroxysteroid Dehydrogenase Type 1— A Tissue-Specific Amplifier of Glucocorticoid Action1Endocrinology, 2001
- Reduction of the Potential Anticancer Drug Oracin in the Rat Liver In-vitroJournal of Pharmacy and Pharmacology, 2000
- Sex differences in stereospecificity of oracin reductases in ratin vitro andin vivoChirality, 1999
- High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin: Interspecies comparisonJournal of Chromatography A, 1998
- G2 cell cycle arrest and apoptosis are induced in Burkitt's lymphoma cells by the anticancer agent oracinFEBS Letters, 1997
- The nature of chiral recognition: Is it a three-point interaction?Chirality, 1997
- Lack of cardiotoxicity of a new antineoplastic agent, a synthetic derivative of indenoisochinoline: comparison with daunorubicin in rabbitsArchives of Toxicology, 1996
- High-performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracineJournal of Chromatography B: Biomedical Sciences and Applications, 1996
- Mutagenicity of cytostatic drugs in a bacterial systemFolia Microbiologica, 1995
- 11β-hydroxysteroid dehydrogenase mediates reductive metabolism of xenobiotic carbonyl compoundsBiochemical Pharmacology, 1994